Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
YARDLEY, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
-
NAVIGATE II: XHANCE produced significant improvement in both co-primary outcome measures, congestion/obstruction at week four and total polyp grade at week 16 EXHANCE-12: Over one year of treatment,...
-
YARDLEY, Pa., June 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
-
YARDLEY, Pa., June 11, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the...
-
YARDLEY, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public...
-
YARDLEY, Pa., June 04, 2018 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission...
-
Optinose confirms retail pharmacy availability of XHANCE commenced in early April Company reports more than 1,300 physicians have prescribed XHANCE through the Xperience program YARDLEY, Pa., May ...
-
YARDLEY, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
-
YARDLEY, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
-
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...